(Q42578789)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20499141%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20499141%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

Miranda M C van Beers

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20499141%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Melody Sauerborn

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20499141%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Vera Brinks

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20499141%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Huub Schellekens

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20499141%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

25 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20499141%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

published in

Pharmaceutical Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20499141%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20499141%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20499141%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

1812-1824

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20499141%20AND%20SRC:MED&resulttype=core&format=json

Neutralizing antibodies against interferon-Beta

3 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

A critical review of methods for size characterization of non-particulate protein aggregates

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Development of a bioassay for quantification of neutralising antibodies against human interferon-beta in mouse sera.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Immune responses to polysaccharides: lessons from humans and mice

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Effects of protein aggregates: an immunologic perspective

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Immunogenicity of interferon beta: differences among products

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Bioequivalence and the immunogenicity of biopharmaceuticals

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Human immune response to recombinant human proteins

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Toward understanding tryptophan fluorescence in proteins

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

The crystal structure of human interferon beta at 2.2-A resolution

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Structure of the carbohydrate moiety of human interferon-beta secreted by a recombinant Chinese hamster ovary cell line

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Calculation of protein extinction coefficients from amino acid sequence data

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Development of a transgenic mouse model immune tolerant for human interferon Beta.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2916121

Solution behavior of IFN-beta-1a: an empirical phase diagram based approach

16 August 2018

1 reference

12 December 2020

The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b

1 reference

12 December 2020

Immunogenicity of aggregates of recombinant human growth hormone in mouse models

1 reference

12 December 2020

The structure of human interferon-beta: implications for activity

1 reference

12 December 2020

Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo

1 reference

12 December 2020

Development of HSA-free formulations for a hydrophobic cytokine with improved stability

1 reference

12 December 2020

Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta

1 reference

12 December 2020

Antibody Response to Aggregated Human Interferon Alpha2b in Wild-type and Transgenic Immune Tolerant Mice Depends on Type and Level of Aggregation

1 reference

12 December 2020

Stability of human interferon-beta 1: oligomeric human interferon-beta 1 is inactive but is reactivated by monomerization

1 reference

12 December 2020

The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model

1 reference

12 December 2020

Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis

1 reference

12 December 2020

Stabilization of a hydrophobic recombinant cytokine by human serum albumin

1 reference

12 December 2020

Aggregation and precipitation of human relaxin induced by metal-catalyzed oxidation

1 reference

12 December 2020

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

1 reference

12 December 2020

Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice

1 reference

12 December 2020

Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?

1 reference

12 December 2020

Reflections on the immunogenicity of therapeutic proteins

1 reference

12 December 2020

Immunological mechanism underlying the immune response to recombinant human protein therapeutics

1 reference

12 December 2020

Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments

1 reference

12 December 2020

Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity

1 reference

12 December 2020

10.1007/S11095-010-0172-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20499141%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20499141%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

PubMed publication ID

20499141

1 reference